Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
...iagnosi...
Colorectal carcinoma patients being cons...
...p.V600 (BRAF c. 1799 (p.V600) mutational...
...mutational analysis should be performed in defic...
...d order mismatch repair status testing in pati...
...sufficient evidence to recommend BRAF c.1799 p.V6...
...ere is insufficient evidence to recomm...
...insufficient evidence to recommend PTEN anal...
...recurrent colorectal carcinoma tissues...
...lin fixed paraffin embedded tissue is an...
...tories must use validated colorectal...
...olecular biomarker testing for colorectal ca...
...must validate the performance of IHC testing fo...
...st provide clinically appropriate turna...
...IHC biomarker testing in colorectal carci...
...hould establish policies to ensure efficient...
Members of the patient’s medical tea...
...ories that require send out of tests for treatm...
...ogists must evaluate candidate specimens for biom...
...oratories should use colorectal carcinoma mole...
...rectal carcinoma molecular biomarker r...
...inoma molecular biomarker testing reports shoul...
...must incorporate colorectal carcinoma mol...
...ble 1. Outcomes of RAS Mutations and Ant...
...dance Rates Between Primary and Metastatic Le...